1. Home
  2. CPRX vs HASI Comparison

CPRX vs HASI Comparison

Compare CPRX & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPRX
  • HASI
  • Stock Information
  • Founded
  • CPRX 2002
  • HASI 1981
  • Country
  • CPRX United States
  • HASI United States
  • Employees
  • CPRX N/A
  • HASI N/A
  • Industry
  • CPRX Biotechnology: Pharmaceutical Preparations
  • HASI Real Estate Investment Trusts
  • Sector
  • CPRX Health Care
  • HASI Real Estate
  • Exchange
  • CPRX Nasdaq
  • HASI Nasdaq
  • Market Cap
  • CPRX 2.9B
  • HASI 3.4B
  • IPO Year
  • CPRX 2006
  • HASI 2013
  • Fundamental
  • Price
  • CPRX $20.78
  • HASI $26.43
  • Analyst Decision
  • CPRX Strong Buy
  • HASI Strong Buy
  • Analyst Count
  • CPRX 6
  • HASI 9
  • Target Price
  • CPRX $32.83
  • HASI $38.33
  • AVG Volume (30 Days)
  • CPRX 1.4M
  • HASI 1.7M
  • Earning Date
  • CPRX 08-06-2025
  • HASI 07-31-2025
  • Dividend Yield
  • CPRX N/A
  • HASI 6.34%
  • EPS Growth
  • CPRX 178.13
  • HASI N/A
  • EPS
  • CPRX 1.57
  • HASI 1.08
  • Revenue
  • CPRX $534,645,999.00
  • HASI $126,702,000.00
  • Revenue This Year
  • CPRX $16.37
  • HASI $189.49
  • Revenue Next Year
  • CPRX $8.80
  • HASI $14.03
  • P/E Ratio
  • CPRX $13.34
  • HASI $24.51
  • Revenue Growth
  • CPRX 29.97
  • HASI N/A
  • 52 Week Low
  • CPRX $15.34
  • HASI $21.98
  • 52 Week High
  • CPRX $26.58
  • HASI $36.56
  • Technical
  • Relative Strength Index (RSI)
  • CPRX 38.36
  • HASI 47.23
  • Support Level
  • CPRX $20.62
  • HASI $26.36
  • Resistance Level
  • CPRX $22.10
  • HASI $27.69
  • Average True Range (ATR)
  • CPRX 0.60
  • HASI 0.83
  • MACD
  • CPRX 0.06
  • HASI -0.04
  • Stochastic Oscillator
  • CPRX 50.34
  • HASI 21.96

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.

Share on Social Networks: